These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25808739)

  • 1. Prostate cancer marker panel with single cell sensitivity in urine.
    Nickens KP; Ali A; Scoggin T; Tan SH; Ravindranath L; McLeod DG; Dobi A; Tacha D; Sesterhenn IA; Srivastava S; Petrovics G
    Prostate; 2015 Jun; 75(9):969-75. PubMed ID: 25808739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
    Laxman B; Morris DS; Yu J; Siddiqui J; Cao J; Mehra R; Lonigro RJ; Tsodikov A; Wei JT; Tomlins SA; Chinnaiyan AM
    Cancer Res; 2008 Feb; 68(3):645-9. PubMed ID: 18245462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.
    Rice KR; Chen Y; Ali A; Whitman EJ; Blase A; Ibrahim M; Elsamanoudi S; Brassell S; Furusato B; Stingle N; Sesterhenn IA; Petrovics G; Miick S; Rittenhouse H; Groskopf J; McLeod DG; Srivastava S
    Clin Cancer Res; 2010 Mar; 16(5):1572-6. PubMed ID: 20160063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.
    He J; Schepmoes AA; Shi T; Wu C; Fillmore TL; Gao Y; Smith RD; Qian WJ; Rodland KD; Liu T; Camp DG; Rastogi A; Tan SH; Yan W; Mohamed AA; Huang W; Banerjee S; Kagan J; Srivastava S; McLeod DG; Srivastava S; Petrovics G; Dobi A; Srinivasan A
    J Transl Med; 2015 Feb; 13():54. PubMed ID: 25889691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
    Ouyang B; Bracken B; Burke B; Chung E; Liang J; Ho SM
    J Urol; 2009 Jun; 181(6):2508-13; discussion 2513-4. PubMed ID: 19371911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
    Sroka WD; Adamowski M; Słupski P; Siódmiak J; Jarzemski P; Odrowąż-Sypniewska G; Marszałł MP
    Int J Biol Markers; 2015 Nov; 30(4):e401-6. PubMed ID: 25982684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.
    Pal RP; Kockelbergh RC; Pringle JH; Cresswell L; Hew R; Dormer JP; Cooper C; Mellon JK; Barwell JG; Hollox EJ
    BJU Int; 2016 Apr; 117(4):686-96. PubMed ID: 26471473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
    Pellegrini KL; Patil D; Douglas KJS; Lee G; Wehrmeyer K; Torlak M; Clark J; Cooper CS; Moreno CS; Sanda MG
    Prostate; 2017 Jun; 77(9):990-999. PubMed ID: 28419548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
    Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
    Zehentner BK; Secrist H; Zhang X; Hayes DC; Ostenson R; Goodman G; Xu J; Kiviat M; Kiviat N; Persing DH; Houghton RL
    Mol Diagn Ther; 2006; 10(6):397-403. PubMed ID: 17154657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
    Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
    BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
    Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
    Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.